scholarly journals Increased risk of second malignancies in chronic lymphocytic leukaemia patients as compared with follicular lymphoma patients: a Canadian population-based study

2013 ◽  
Vol 109 (5) ◽  
pp. 1287-1290 ◽  
Author(s):  
S Beiggi ◽  
J B Johnston ◽  
M D Seftel ◽  
M W Pitz ◽  
R Kumar ◽  
...  
Keyword(s):  
Follicular Lymphoma ◽  
Chronic Lymphocytic Leukaemia ◽  
Lymphocytic Leukaemia ◽  
Population Based ◽  
Second Malignancies ◽  
Population Based Study ◽  
Canadian Population ◽  
Increased Risk

scholarly journals The Impact of Prior Malignancies on Second Malignancies and Survival in MM Patients: A Population-Based Study

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 3246-3246
Author(s):  
Gudbjorg Jonsdottir ◽  
Sigrún H. Lund ◽  
Magnus Björkholm ◽  
Ingemar Turesson ◽  
Anders Wahlin ◽  
...  
Keyword(s):  
Cancer Diagnosis ◽  
Hematological Malignancies ◽  
Cox Regression ◽  
Population Based ◽  
Second Malignancies ◽  
Advisory Committees ◽  
Population Based Study ◽  
Risk Of Death ◽  
Increased Risk ◽  
Prior Malignancy

Abstract Background Awareness of second malignancies in patients with multiple myeloma (MM) has been increasing during recent years. We have previously shown that second malignancies are associated with a decreased life expectancy in MM patients. Information regarding prior and second malignancies in MM is limited as these patients are often excluded from clinical trials and previously published results from other groups have been conflicting. In the present study we aimed to evaluate two hypotheses. Firstly we hypothesize that prior malignancy is a proxy for genetic instability that could be a risk factor for subsequent malignancy development in MM patients. There is limited data regarding this association in the literature and in two recent registry studies the results were inconclusive. Secondly, to further assess the clinical implication of prior malignancies in MM patients we assessed survival in these patients compared to MM patients without a history of prior malignancy. Patients and Methods All patients diagnosed with MM from January 1, 1973 to December 31, 2013 were identified from the Swedish Cancer Register. All prior and subsequent malignant diagnoses were identified through cross-linkage within the registry. A Cox regression model was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) where prior malignancy was compared in MM patients who developed a subsequent malignancy and MM patients who did not. In another Cox regression model, survival was compared in MM patients with and without a prior malignancy. The same method was used to estimate if there was a dose-dependent relationship, i.e. if an increasing number of prior malignancies was associated with a poorer outcome. Results A total of 22,359 patients were diagnosed with MM during the study period. Of these, 2,620 (12%) patients had one or more prior malignancy diagnosis at the time of MM diagnosis and 1,243 (6%) patients developed subsequent malignancies. Among the MM patients who developed a subsequent malignancy, 148 (12%) had a prior malignancy diagnosis. Hematological malignancies were 7% of prior malignancies and 17% of subsequent malignancies. MM patients with a prior malignancy diagnosis did not have increased risk of developing a subsequent malignancy compared to MM patients without a prior malignancy (HR 1.0, 95% CI 0.9-1.2). MM patients with a prior malignancy diagnosis had a statistically significant 10% increased risk of death (HR=1.1, 95% CI 1.1-1.2, p<0.001) compared to MM patients without a prior malignancy diagnosis. MM patients with 2 or more prior malignancy diagnoses had a 20% increased risk of death (HR=1.2, 95% CI 1.1-1.4, p=0.002) compared to MM patients without a prior malignancy diagnosis (Figure). Summary and Conclusions In our large population-based study we found that prior malignancy negatively impacts survival in MM patients and that more than one prior malignancy decreases survival even further. Interestingly, a prior malignancy did not increase the risk of developing a subsequent malignancy in MM patients. We confirmed prior reports of solid tumors being more common than hematological malignancies, both prior and subsequent to the MM diagnosis. A prior malignancy was associated with a reduced survival in MM patients without being a risk factor for subsequent malignancies. The underlying explanation for this is probably multifactorial, and could include reduced dose intensity of chemotherapy, complications from treatment, or that MM that develops after another malignancy might be biologically different. Given the increase of cancer survivors in general, our findings are of importance both for the individual patients and their families as well as for the treating physician. Figure Survival in MM patients without a prior cancer diagnosis compared to MM patients with one and two or more prior cancer diagnoses Figure. Survival in MM patients without a prior cancer diagnosis compared to MM patients with one and two or more prior cancer diagnoses Disclosures Landgren: Takeda: Membership on an entity's Board of Directors or advisory committees; Merck: Membership on an entity's Board of Directors or advisory committees; Medscape: Employment, Other: Chairman for Medscape Myeloma Program; Amgen: Speakers Bureau; Celgene: Speakers Bureau; BMS: Speakers Bureau.

scholarly journals Conditional relative survival among patients with chronic lymphocytic leukaemia: A population‐based study in the Netherlands

eJHaem ◽  
2021 ◽  
Author(s):  
Lina Straten ◽  
Mark‐David Levin ◽  
Otto Visser ◽  
Eduardus F.M. Posthuma ◽  
Jeanette K. Doorduijn ◽  
...  
Keyword(s):  
The Netherlands ◽  
Chronic Lymphocytic Leukaemia ◽  
Lymphocytic Leukaemia ◽  
Relative Survival ◽  
Population Based ◽  
Population Based Study

scholarly journals The impact of prior malignancies on the development of second malignancies and survival in follicular lymphoma: A population‐based study

eJHaem ◽  
2020 ◽  
Vol 1 (2) ◽  
pp. 489-497
Author(s):  
Manette A.W. Dinnessen ◽  
Otto Visser ◽  
Sanne H. Tonino ◽  
Marjolein W.M. Poel ◽  
Nicole M.A. Blijlevens ◽  
...  
Keyword(s):  
Follicular Lymphoma ◽  
Population Based ◽  
Second Malignancies ◽  
Population Based Study ◽  
The Impact

scholarly journals Detailing the epidemiological and clinical characteristics of chronic lymphocytic leukaemia in Portugal—Results from a population-based cancer registry cohort study

PLoS ONE ◽  
2021 ◽  
Vol 16 (10) ◽  
pp. e0258423
Author(s):  
Fábio Cardoso Borges ◽  
Adriana Ramos ◽  
António Lourenço ◽  
Maria Gomes da Silva ◽  
Ana Miranda ◽  
...  
Keyword(s):  
Cohort Study ◽  
Chronic Lymphocytic Leukaemia ◽  
Cancer Registry ◽  
Clinical Presentation ◽  
Lymphocytic Leukaemia ◽  
Population Based ◽  
Incidence Rates ◽  
European Population ◽  
Second Malignancies ◽  
Binet Stage

Background Chronic lymphocytic leukaemia (CLL) is the most common leukaemia among adults in western countries. Considering the increasing incidence and prevalence of this condition, it is highly relevant to better characterise these patients in Portugal, where data is still scarce. Methods To determine incidence, clinical presentation, survival and second malignancies, a population-based historical cohort study was conducted. Cases of interest were identified through the South Region Cancer Registry database and additional data sources. Patients aged ≥18 years, with a confirmed diagnosis of CLL or small lymphocytic lymphoma between January 1st, 2013 and December 31st, 2014 were included. Patients were followed‐up until death or cut-off date (December 31st, 2019). Results A total of 496 patients were included and median follow-up time was 5.46 years. Crude incidence rates were 5.03 and 5.22 per 100,000 inhabitants for 2013 and 2014, respectively, and age-adjusted incidence rates were 3.18:100,000 European population for 2013 and 3.35:100,000 European population for 2014. Median age at diagnosis was 71 years and the male/female ratio was 1.40. The majority of patients had leukemic presentation of the disease (86.09%), was diagnosed in Binet stage A (75.58%) and did not present B symptoms (84.01%), anaemia (haemoglobin ≤10g/dL; 90.63%) nor thrombocytopenia (platelet count ≤100 000/μL; 91.73%). Five-year overall survival (OS) rate was 70.53% (95%CI 66.31–74.34) and age, lactate dehydrogenase, Binet stage and a ≥5 Charlson comorbidity index score were independently associated with OS. Standardised-incidence ratios for any second malignancy and cutaneous squamous cell carcinoma were 1.59 (95%CI 1.19–2.08) and 10.15 (95%CI 6.28–15.51), respectively. Conclusion Incidence, clinical presentation and survival of CLL Portuguese patients are similar to those reported for other western countries. The increased risk of second malignancies raises concerns and needs adequate clinical watchfulness.

scholarly journals The effectiveness of ibrutinib in chronic lymphocytic leukaemia: a nationwide, population‐based study in the Netherlands

2020 ◽  
Vol 188 (6) ◽  
Author(s):  
Lina Straten ◽  
Mark‐David Levin ◽  
Otto Visser ◽  
Nicole M.A. Blijlevens ◽  
Jan J. Cornelissen ◽  
...  
Keyword(s):  
The Netherlands ◽  
Chronic Lymphocytic Leukaemia ◽  
Lymphocytic Leukaemia ◽  
Population Based ◽  
Population Based Study
Sign in / Sign up

Export Citation Format

Share Document